Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection
Mem. Inst. Oswaldo Cruz
;
105(5): 687-691, Aug. 2010. graf
Article
in English
| LILACS
| ID: lil-557231
ABSTRACT
The potential use of the Trypanosoma cruzi metacyclic trypomastigote (MT) stage-specific molecule glycoprotein-82 (gp82) as a vaccine target has not been fully explored. We show that the opsonization of T. cruzi MT with gp82-specific antibody prior to mucosal challenge significantly reduces parasite infectivity. In addition, we investigated the immune responses as well as the systemic and mucosal protective immunity induced by intranasal CpG-adjuvanted gp82 vaccination. Spleen cells from mice immunized with CpG-gp82 proliferated and secreted IFN-γ in a dose-dependent manner in response to in vitro stimulation with gp82 and parasite lysate. More importantly, these CpG-gp82-immunized mice were significantly protected from a biologically relevant oral parasite challenge.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Trypanosoma cruzi
/
Protozoan Proteins
/
Variant Surface Glycoproteins, Trypanosoma
/
Protozoan Vaccines
/
Chagas Disease
Limits:
Animals
Language:
English
Journal:
Mem. Inst. Oswaldo Cruz
Journal subject:
Tropical Medicine
/
Parasitology
Year:
2010
Type:
Article
Affiliation country:
Brazil
/
United States
Institution/Affiliation country:
Saint Louis University/US
/
Universidade Federal de São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS